Patients Who Switched From Weight-Loss Shots to the Wegovy Pill Lost 4.1% of Body Weight in Three Months
5 Articles
5 Articles
People with overweight or obesity who exchanged injectable medicines for weight loss for a Wegovy Semaglutide tablet version of the New Nordisk lost, on average, 4.1% of body weight after three months, according to new data released on Wednesday (30), during the Congress of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Weight loss pens: Nail removal is 4 times more common in GLP-1 users, shows unprecedented study For…
A study found that patients who switched from injectable obesity treatment to pill-form treatment lost an average of 4 kg more in three months.
They left injectable treatments such as Wegovy and Zepbound and started taking semaglutide orally. The first real-life data show what happened to the weight of these patients after the change.
A study has revealed that patients who were using injectable obesity medications continued to lose weight after switching to the oral medication Ugobi. This suggests that oral obesity medications may not only reduce the burden of injections but also be effective in promoting weight loss. Novo Novo presented these results at the European Association for the Study of Diabetes (EASD) annual scientific meeting held in Milan, Italy, on the 30th of la…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
